Indications and Purposes
| 1 Indications And Usage Iressa Is Indicated For The First-Line Treatment Of Patients With Metastatic Non-Small Cell Lung Cancer (Nsclc) Whose Tumors Have Epidermal Growth Factor Receptor (Egfr) Exon 19 Deletions Or Exon 21 (L858r) Substitution Mutations As Detected By An Fda-Approved Test [See Clinical Studies (14) ] . Limitation Of Use: Safety And Efficacy Of Iressa Have Not Been Established In Patients With Metastatic Nsclc Whose Tumors Have Egfr Mutations Other Than Exon 19 Deletions Or Exon 21 (L858r) Substitution Mutations [See Clinical Studies (14) ] . Iressa Is A Tyrosine Kinase Inhibitor Indicated For The First-Line Treatment Of Patients With Metastatic Non-Small Cell Lung Cancer (Nsclc) Whose Tumors Have Epidermal Growth Factor Receptor (Egfr) Exon 19 Deletions Or Exon 21 (L858r) Substitution Mutations As Detected By An Fda-Approved Test. (1) Limitation Of Use: Safety And Efficacy Of Iressa Have Not Been Established In Patients Whose Tumors Have Egfr Mutations Other Than Exon 19 Deletions Or Exon 21 (L858r) Substitution Mutations. (1) |
All Formulated Excipients (0 Total)
None
Active Ingredients ( 1 Total)
| Name | Structure | ZINC ID(s) |
|---|---|---|
| 1. Gefitinib |
|
ZINC19632614 |